Screening for prostate cancer is a controversial topic within the field of urology. Instead of adopting a 'one size fits all' approach, physicians are likely to perform personalized risk assessment to minimize the risk of negative consequences, such as anxiety, unnecessary testing and biopsies, overdiagnosis, and overtreatment. In this Review, Monique J. Roobol and Sigrid J. Carlsson focus on the effects of shifts in attitude towards PSA testing on risk stratification.
- Monique J. Roobol
- Sigrid V. Carlsson
